Clinical Trial Detail

NCT ID NCT02754362
Title A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors New York University School of Medicine
Indications

glioblastoma multiforme

Therapies

Poly ICLC

Bevacizumab

Age Groups: adult

No variant requirements are available.